Non-Muscle Invasive Bladder Cancer Overview
Learn About Non-Muscle Invasive Bladder Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Physicians' Clinic Of Iowa, PC
Luke Brunkhorst is an Urologist in Cedar Rapids, Iowa. Dr. Brunkhorst and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Brunkhorst is currently accepting new patients.
Physicians' Clinic Of Iowa, PC
William Fusselman is a Hematologist Oncology specialist and an Oncologist in Cedar Rapids, Iowa. Dr. Fusselman and is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Hodgkin Lymphoma, Breast Cancer, Schnitzler Syndrome, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Fusselman is currently accepting new patients.
Physicians' Clinic Of Iowa, PC
Steven Mindrup is an Urologist in Cedar Rapids, Iowa. Dr. Mindrup and is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Urinary Tract Infection in Children, Urinary Incontinence, Hydronephrosis, Ureteroscopy, and Nephrectomy. Dr. Mindrup is currently accepting new patients.
Summary: This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from s...
Summary: This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.